Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in β-thalassemia major patients

Hemoglobin

Volumn 30, Issue 2, 2006, Pages 257-262

  Wang, Chung Hsing ^a   Wu, Kang Hsi ^a   Tsai, Fuu Jen ^a   Peng, Ching Tien ^a   Tsai, Chang Hai ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Thalassemia (thal) major; Endocrinopathies; Iron chelation therapy

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT;

ADULT; BETA THALASSEMIA; BLOOD TRANSFUSION; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFICACY; ENDOCRINE DISEASE; FEMALE; GONAD DYSFUNCTION; GROWTH HORMONE DEFICIENCY; HUMAN; IRON CHELATION; IRON STORAGE; LONGEVITY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; THALASSEMIA MAJOR;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; COMBINED MODALITY THERAPY; DEFEROXAMINE; DIABETES MELLITUS; DWARFISM, PITUITARY; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOGONADISM; INFUSIONS, PARENTERAL; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PATIENT COMPLIANCE; PUBERTY, DELAYED; PYRIDONES; SUBCUTANEOUS TISSUE;

EID: 33745533131     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260600642609     Document Type: Conference Paper

References (18)

1. Olivieri NF. Medical progress: the β-thalassemias. N Engl J Med 1999; 341(2):99-109.
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β thalassemia. N Engl J Med 1994; 331(9):574-578.
3. Rund D, Rachmilewitz E. Thalassemia major 1995: older patients, new therapy. Blood Rev 1995; 9(1):25-32.
4. Aydinok Y, Darcan S, Polat A, Kavakli K, Nigli G, Coker M, Kantar M, Cetingul M. Endocrine complications in patients with β-thalassemia major. J Trop Pediatr 2002; 48(1):50-54.
5. Vullo C, De Sanctis V, Katz M. Endocrine abnormalities in thalassemia. Ann NY Acad Sci 1990; 612:293-310.
6. Genuth S, Alberti KG, Bennett P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26(11):3160-3167.
7. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in β-thalassemia major in a developing country. J Pediatr Endocrinol 2000; 13(6):651-656.
8. Masala A, Meloni T, Gallisai D, Alagna S, Rovasio PP, Rassu S, Melia AF. Endocrine functioning in multi-transfused prepubertal patients with homozygous β-thalassemia. J Clin Endocrinol Metab 1984; 58(4):667-670.
9. Italian Working Group on Endocrine Complications in Non-Endocrine Disease. Multicenter study of prevalence of endocrine complication in thalassemia major. Clin Endocrinol 1995; 42(6):581-586.
10. Chern JP, Lin KH, Lu MY, Lin DT, Lin KS, Chen JD, Fu CC. Abnormal glucose tolerance in transfusion-dependent β-thalassemia patients. Diabetes Care 2001; 24(3):850-854.
11. Costin G, Kogut MD, Hyman C, Ortega JA. Carbohydrate metabolism and pancreatic islet-cell function in thalassemia major. Diabetes 1977; 26(3):230-240.
12. Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C, Sacchetti L, Piga A, Pagano G. Insulin resistance and hyperinsulinemia in homozygous β-thalassemia. Metabolism 1995; 44(3):281-286.
13. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T. High prevalence of diabetes mellitus among adult β-thalassemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1999; 11(9):1033-1036.
14. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993; 77(2):478-483.
15. Saka N, Sukur M, Bundak R, Anak S, Neyzi O, Gedikoglu G. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab 1995; 8(3):181-186.
16. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freeman MH, Holland FJ. Effects of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990; 323(11):713-719.
17. Kontoghiorghes GJ, Aldouri MA, Sheppard L. I-2-dimethyl-3-hydroxypyrid-4- one an orally active chelator for treatment of iron overload. Lancet 1987; 1(8545):1294-1295.
18. Shalev O, Repka T, Goldfarb A. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells from both in vitro and in vivo. Blood 1995; 86(5):2008-2013.